Following a directed appraisal
AWMSG advice |
||||
| Status: Recommended | ||||
Cytisinicline (cytisine) is recommended as an option for use within NHS Wales for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. |
||||
|
||||
Medicine details |
||||
| Medicine name | cytisinicline (cytisine) | |||
| Formulation | 1.5 mg tablet | |||
| Reference number | 3708 | |||
| Indication | Smoking cessation and reduction of nicotine cravings in smokers willing to stop smoking |
|||
| Company | Generic medicine | |||
| BNF chapter | Central nervous system | |||
| Assessment type | Directed | |||
| Status | Recommended | |||
| Advice number | 0424 | |||
| NMG meeting date | 05/06/2024 | |||
| AWMSG meeting date | 09/07/2024 | |||
| Ratification by Welsh Government | 10/07/2024 | |||
| Date of issue | 10/07/2024 | |||
| Further information Cytisinicline is an alternative name for cytisine |
||||